Q-omics provides the consensus-scored PKD1P6 profile across patient tissues and cancer cell-line models. PKD1P6 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PKD1P6 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PKD1P6 RNA expression shows 20,581 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where PKD1P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PKD1P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PKD1P6 survival associations across molecular data types. PKD1P6 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PKD1P6 RNA expression–survival associations across cancer types. High PKD1P6 expression shows unfavorable associations in KICH, KIRC and THCA, but favorable associations in HNSC, UCS and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PKD1P6 RNA expression.
This table summarizes PKD1P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PKD1P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PKD1P6 shows lower tumor expression in THCA and BRCA and higher tumor expression in KIRC, KIRP, LIHC and COAD. The KIRC box plot shows higher PKD1P6 RNA expression in tumor versus normal tissue (log2 FC = +0.717, t-test p < 0.001).
This table shows molecular features associated with PKD1P6 in patient tissues and cancer cell lines. In patient samples, PKD1P6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
